For years, real-world evidence strategies across pharmaceutical organizations have been built primarily on administrative claims data. Claims datasets have long served as the backbone for understanding utilization trends, reimbursement activity, and treatment adoption patterns.
They remain valuable.
But as access dynamics grow more complex and decision timelines compress, the limits of a claims-first evidence model are becoming increasingly visible.
Claims can tell you that a therapy was prescribed, filled, switched, or discontinued. What they cannot consistently explain is why those events occurred in clinical practice.
And in today’s market access environment, that distinction matters.
The Limits of Claims-Only Evidence
Administrative claims provide an essential view of healthcare activity. They capture billing codes, procedures, diagnoses, and reimbursement events across large populations.
But claims data was never designed to fully represent clinical decision-making.
For pharmaceutical teams evaluating real-world performance, this creates important blind spots.
Claims can show that:
- a therapy was initiated
- a treatment switch occurred
- utilization slowed or accelerated
What claims typically cannot reveal is:
- disease severity at the time of prescribing
- the clinical rationale behind therapy selection
- treatment sequencing considerations
- documentation-driven access barriers
- physician intent within complex care pathways
These elements often determine whether a therapy gains traction in real-world practice.
Without that context, organizations may detect performance changes without fully understanding the drivers behind them.
A Shift Toward EMR-First Evidence
Across Market Access, HEOR, Medical Affairs, and Commercial teams, a new evidence model is emerging.
Rather than beginning with administrative claims and attempting to infer clinical context through proxies, organizations are increasingly starting with chart-level clinical data.
This EMR-first approach captures the clinical environment in which treatment decisions actually occur.
Electronic medical records contain structured and unstructured information such as:
- physician notes
- laboratory values
- diagnostic results
- medication orders
- vital signs
- treatment documentation
These data elements provide insight into disease progression, therapeutic rationale, and patient management decisions that are often invisible in administrative claims.
When claims data is layered onto this clinical foundation, organizations gain a more complete longitudinal view of care — combining clinical context with utilization patterns.
Why Clinical Context Matters for Market Access
The importance of EMR-first evidence becomes especially clear during critical decision windows across the product lifecycle.
Teams evaluating launch performance, payer positioning, and treatment adoption increasingly need to answer questions such as:
- Are prescribing patterns aligned with disease severity expectations?
- Are health systems adopting therapy in line with treatment guidelines?
- Are sequencing decisions influenced by payer requirements or documentation burdens?
- Are early discontinuation patterns linked to clinical factors or access barriers?
Claims data can highlight these patterns. EMR data helps explain them.
For organizations operating in an environment of increasing payer scrutiny and compressed contracting cycles, understanding the clinical reality behind utilization trends can materially improve how strategy is refined.
Introducing EMRClaims+
EMRClaims+® was designed around this EMR-first evidence model.
Rather than starting with claims and supplementing limited clinical proxies, EMRClaims+ begins with chart-level electronic medical record data and applies claims linkage to extend longitudinal insight. The platform integrates clinical records with administrative data to provide a clearer view of how therapy progresses in real-world care environments.
eMAX_Health_EMRClaims
By grounding analysis in clinical documentation before layering in claims activity, organizations can interpret real-world performance with greater precision and reduced ambiguity.
From Data to Decision-Grade Insight
As pharmaceutical organizations evaluate how evidence informs market access strategy, the conversation is shifting.
The question is no longer simply how much data is available.
It is whether that data reflects clinical reality.
EMR-first evidence models help close the gap between utilization signals and the clinical decisions that drive them.
For teams responsible for demonstrating value, refining access strategy, and navigating evolving payer expectations, that distinction increasingly determines whether insight translates into action.